Compared with Smad3, Smad2 may play an antagonistic role in the EMT process in vivo: In fact, loss of Smad2 has been frequently shown in human skin cancers, and Smad2 deficiency in keratinocytes promotes EMT accelerating skin tumorigenesis [50]. This evidence concerns the gene SMAD3 and skin neoplasm.